Bank of Montreal’s Oramed Pharmaceuticals ORMP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-249,200
Closed -$1.35K 4338
2022
Q2
$1.35K Buy
+249,200
New +$1.33M ﹤0.01% 2124
2021
Q2
Sell
-1,600
Closed -$16K 4573
2021
Q1
$16K Hold
1,600
﹤0.01% 4153
2020
Q4
$7K Hold
1,600
﹤0.01% 4723
2020
Q3
$4K Hold
1,600
﹤0.01% 4519
2020
Q2
$5K Hold
1,600
﹤0.01% 4415
2020
Q1
$5K Sell
1,600
-2,400
-60% -$10.5K ﹤0.01% 3686
2019
Q4
$20K Buy
4,000
+2,400
+150% +$8.99K ﹤0.01% 4320
2019
Q3
$5K Hold
1,600
﹤0.01% 4556
2019
Q2
$6K Hold
1,600
﹤0.01% 4650
2019
Q1
$6K Hold
1,600
﹤0.01% 3999
2018
Q4
$5K Hold
1,600
﹤0.01% 4093
2018
Q3
$8K Sell
1,600
-1,000
-38% -$5.19K ﹤0.01% 3995
2018
Q2
$19K Hold
2,600
﹤0.01% 3759
2018
Q1
$17K Hold
2,600
﹤0.01% 3604
2017
Q4
$23K Buy
2,600
+1,000
+63% +$9.56K ﹤0.01% 3546
2017
Q3
$16K Hold
1,600
﹤0.01% 3585
2017
Q2
$12K Hold
1,600
﹤0.01% 3678
2017
Q1
$10K Hold
1,600
﹤0.01% 3553
2016
Q4
$10K Buy
+1,600
New +$10.4K ﹤0.01% 3605
2016
Q3
Sell
-1,580
Closed -$13K 4150
2016
Q2
$13K Hold
1,580
﹤0.01% 3520
2016
Q1
$11K Hold
1,580
﹤0.01% 3592
2015
Q4
$14K Buy
+1,580
New +$12K ﹤0.01% 3522

Other funds holding ORMP

Bank of Montreal's ORMP Position: Q3 2022 in Review

Bank of Montreal sold out of Oramed Pharmaceuticals (ORMP) in Q3 2022, closing a stake of 249,200 shares — an estimated $1.35K sold.

Bank of Montreal first reported a position in ORMP in Q4 2015 and held it in 22 quarters. The position peaked at $23K in Q4 2017. 71 funds tracked by Wall St. Rank hold ORMP as of Q3 2022.

  • Bank of Montreal reported no remaining Oramed Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Bank of Montreal sold 249,200 Oramed Pharmaceuticals shares in Q3 2022, an estimated $1.35K.
  • Bank of Montreal first reported a position in Oramed Pharmaceuticals in Q4 2015 and held it in 22 quarters.
  • Bank of Montreal's Oramed Pharmaceuticals position peaked at $23K in Q4 2017.
  • 71 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2022.

Based on Bank of Montreal's 13F filing for Q3 2022, filed 10 Nov 2022.